Rheumatoid arthritis patients on TNFi at high risk of developing psoriasis
Rheumatoid arthritis patients on TNFi at high risk of developing psoriasis suggests a new study published in the Scientific reports.
Rheumatoid arthritis (RA) is a common chronic autoimmune disorder primarily attacking the joints, affecting between 0.5 and 1% of the world population. Rheumatoid arthritis is characterized by joint pain, tenderness, swelling, and joint stiffness. While the cause of Rheumatoid arthritis is not certain, risk factors include genetics, smoking, obesity, sex, and age. Similar to other autoimmune diseases, RA predominantly affects females, with a 2:1 to 3:1 female to male ratio. While RA can develop at any age, typical onset occurs between 30 and 50 years. RA is commonly treated with immunosuppressants such as methotrexate, hydroxychloroquine, sulfasalazine, or leflunomide, T-cell costimulatory inhibitors such as abatacept, interleukin-6 receptor (IL-6R) antibodies such as tocilizumab, Janus kinase (JAK) inhibitors, and tumor necrosis factor (TNF) inhibitors such as certolizumab pegol, adalimumab, golimumab, infliximab, and etanercept4.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.